Your browser doesn't support javascript.
loading
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity.
Kurucu, Nilgün; Kutluk, Tezer; Saglam, Arzu; Cagdas, Deniz; Haliloglu, Mithat; Salanci, Bilge Volkan; Aydin, Burça; Yalçin, Bilgehan; Varan, Ali; Üner, Aysegül.
Afiliación
  • Kurucu N; Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
  • Kutluk T; Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
  • Saglam A; Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Cagdas D; Department of Pediatric Immunology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Haliloglu M; Department of Pediatric Radiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Salanci BV; Faculty of Medicine, Department of Nuclear Medicine, Hacettepe University, Ankara, Turkey.
  • Aydin B; Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
  • Yalçin B; Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
  • Varan A; Department of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
  • Üner A; Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Leuk Lymphoma ; : 1-8, 2024 Jul 05.
Article en En | MEDLINE | ID: mdl-38967495
ABSTRACT
Indolent lymphomas are rare in children and mostly consist of pediatric type follicular (PTFL) and pediatric marginal zone lymphomas (PMZL) and extranodal marginal zone lymphoma (ENMZL). Twenty children with indolent lymphoma (10 PTFL, 6 PMZL, 3 ENMZL, 1 mixed type) among 307 Non-Hodgkin Lymphoma (NHL) were retrospectively evaluated. The mean age of the entire group was 10.4 ± 4.4 and was significantly lower in PTFL than in PMZL. Seven patients (35%) had an associated inborn error of immunity (IEI) which was higher than that seen in aggressive lymphomas (5.9%) (p < 0.0001). Seventeen patients (85%) had stage I/II disease. Two patients received no treatment after surgery. Eleven patients were treated only with 3-6 courses of rituximab. Four patients received 3-6 courses of R-CHOP protocol. The prognosis was excellent Five years overall and event-free survivals were 100% and 85%, respectively.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Turquía